Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Traws Pharma Inc (TRAW)

Traws Pharma Inc (TRAW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,865
  • Shares Outstanding, K 7,991
  • Annual Sales, $ 230 K
  • Annual Income, $ -166,520 K
  • EBIT $ -20 M
  • EBITDA $ -20 M
  • 60-Month Beta 1.78
  • Price/Sales 3.83
  • Price/Cash Flow N/A
  • Price/Book 2.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.91
  • Number of Estimates 1
  • High Estimate -1.91
  • Low Estimate -1.91
  • Prior Year 95.66
  • Growth Rate Est. (year over year) -102.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3700 +17.52%
on 02/19/26
2.9840 -46.05%
on 01/27/26
-0.9700 (-37.60%)
since 01/20/26
3-Month
1.0514 +53.13%
on 12/30/25
2.9840 -46.05%
on 01/27/26
-0.5300 (-24.77%)
since 11/20/25
52-Week
0.9700 +65.98%
on 05/15/25
5.1000 -68.43%
on 02/21/25
-3.0800 (-65.67%)
since 02/20/25

Most Recent Stories

More News
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution;...

TRAW : 1.6100 (+2.55%)
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution;...

TRAW : 1.6100 (+2.55%)
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpile...

TRAW : 1.6100 (+2.55%)
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients

Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid ® -ineligible patients, representing a significant population...

TRAW : 1.6100 (+2.55%)
Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end Significant intellectual property...

TRAW : 1.6100 (+2.55%)
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

SAN DIEGO , Oct. 30, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services...

TRAW : 1.6100 (+2.55%)
Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

DOVER, Del. , Oct. 22, 2025 /PRNewswire/ -- Expert Systems Inc. , a leading life sciences accelerator, announced its continued support for Traws Pharma (NASDAQ: TRAW) as the company initiates...

TRAW : 1.6100 (+2.55%)
Traws Pharma Begins Phase 2 COVID-19 Treatment Study

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

TRAW : 1.6100 (+2.55%)
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Non-inferiority trial versus PAXLOVID ® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment...

TRAW : 1.6100 (+2.55%)
Traws Pharma Appoints New Independent Director and CEO

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

TRAW : 1.6100 (+2.55%)

Business Summary

Traws Pharma Inc. is involved in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Traws Pharma Inc., formerly known as Onconova Therapeutics Inc., is based in NEWTOWN, Pa.

See More

Key Turning Points

3rd Resistance Point 1.8402
2nd Resistance Point 1.7541
1st Resistance Point 1.6821
Last Price 1.6100
1st Support Level 1.5240
2nd Support Level 1.4379
3rd Support Level 1.3659

See More

52-Week High 5.1000
Fibonacci 61.8% 3.5223
Fibonacci 50% 3.0350
Fibonacci 38.2% 2.5477
Last Price 1.6100
52-Week Low 0.9700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar